Vera Therapeutics announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $200M of shares of its Class A common stock. All of the shares are being offered by Vera. J.P. Morgan, TD Cowen and Evercore ISI are acting as joint book-running managers for the proposed offering. LifeSci Capital is acting as lead manager for the proposed offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VERA:
- Vera Therapeutics price target raised to $39 from $25 at JPMorgan
- Alpine Immune Sciences price target raised to $33 from $30 at Oppenheimer
- Vera Therapeutics price target raised to $21 from $16 at Wedbush
- Vera Therapeutics price target raised to $34 from $26 at Oppenheimer
- Vera Therapeutics Reports Positive Phase 2b ORIGIN Trial Results